402 related articles for article (PubMed ID: 25968455)
1. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
Kwek SS; Lewis J; Zhang L; Weinberg V; Greaney SK; Harzstark AL; Lin AM; Ryan CJ; Small EJ; Fong L
Cancer Immunol Res; 2015 Sep; 3(9):1008-16. PubMed ID: 25968455
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
Hodi FS; Lee S; McDermott DF; Rao UN; Butterfield LH; Tarhini AA; Leming P; Puzanov I; Shin D; Kirkwood JM
JAMA; 2014 Nov; 312(17):1744-53. PubMed ID: 25369488
[TBL] [Abstract][Full Text] [Related]
5. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
6. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Jochems C; Tucker JA; Tsang KY; Madan RA; Dahut WL; Liewehr DJ; Steinberg SM; Gulley JL; Schlom J
Cancer Immunol Immunother; 2014 Apr; 63(4):407-18. PubMed ID: 24514956
[TBL] [Abstract][Full Text] [Related]
7. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
[TBL] [Abstract][Full Text] [Related]
8. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
9. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
Oh DY; Cham J; Zhang L; Fong G; Kwek SS; Klinger M; Faham M; Fong L
Cancer Res; 2017 Mar; 77(6):1322-1330. PubMed ID: 28031229
[TBL] [Abstract][Full Text] [Related]
10. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
[TBL] [Abstract][Full Text] [Related]
11. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
Luke JJ; Donahue H; Nishino M; Giobbie-Hurder A; Davis M; Bailey N; Ott PA; Hodi FS
Cancer Immunol Res; 2015 Sep; 3(9):986-91. PubMed ID: 25943535
[TBL] [Abstract][Full Text] [Related]
12. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
13. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
14. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract][Full Text] [Related]
15. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Sharma P; Pachynski RK; Narayan V; Fléchon A; Gravis G; Galsky MD; Mahammedi H; Patnaik A; Subudhi SK; Ciprotti M; Simsek B; Saci A; Hu Y; Han GC; Fizazi K
Cancer Cell; 2020 Oct; 38(4):489-499.e3. PubMed ID: 32916128
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus ipilimumab in advanced melanoma.
Wolchok JD; Kluger H; Callahan MK; Postow MA; Rizvi NA; Lesokhin AM; Segal NH; Ariyan CE; Gordon RA; Reed K; Burke MM; Caldwell A; Kronenberg SA; Agunwamba BU; Zhang X; Lowy I; Inzunza HD; Feely W; Horak CE; Hong Q; Korman AJ; Wigginton JM; Gupta A; Sznol M
N Engl J Med; 2013 Jul; 369(2):122-33. PubMed ID: 23724867
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Beer TM; Kwon ED; Drake CG; Fizazi K; Logothetis C; Gravis G; Ganju V; Polikoff J; Saad F; Humanski P; Piulats JM; Gonzalez Mella P; Ng SS; Jaeger D; Parnis FX; Franke FA; Puente J; Carvajal R; Sengeløv L; McHenry MB; Varma A; van den Eertwegh AJ; Gerritsen W
J Clin Oncol; 2017 Jan; 35(1):40-47. PubMed ID: 28034081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
